Outsourcing has been such an integral part of the bioprocessing industry that BPI made it the focus of its first supplement (September 2003). Since then, manufacturers continue to reach beyond local and national borders to extend their networks of partnerships to emerging markets. Global economics during the past decade have not always made outsourcing easy. Ten years ago, manufacturers faced tough decisions over whether it was more cost effective to outsource or keep process activities in-house (possibly expand or build) while facing the seemingly inevitable ‚Äúcapacity crunch‚ÄĚ that many industry experts had projected.
A 2004 survey revealed that manufacturers were not exactly warming up to the idea of increasing capacity, but rather seemed to favor process improvement and opportunities in emerging markets (1). By some projections, outsourcing (for mammalian cell culture processes especially) would nearly double over the next five years (thanks in part to the ‚Äúcapacity crunch‚ÄĚ), even though most of the industry at that time preferred to keep production in house. By 2007, however, capacity for mammalian cell culture systems had dropped from 76.4% in 2003 to 63.3%. During that same time period, microbial fermentation capacity use declined from 71.0% to 53.8% in 2007 (2).
All that had certain implications for contract manufacturers: ‚ÄúThe industry’s reliance on CMOs is also expected to grow as their capacity provides support for biotherapeutics developers by reducing total risks associated with building additional capacity for products that may not ultimately be approved for commercial production‚ÄĚ (2). In fact, the percentage of manufacturing that was taking place entirely in-house had decreased from 79% in 2003 to 55.6% in 2007 for mammalian cell culture (3). The trend toward increased outsourcing was reportedly due to cost pressures, globalization, and improved technologies.
Also by 2007, the venture capital industry seemed to be finally coming out of the slump it had experienced in the early 2000s (4). Investors remained cautiously optimistic. During the first quarter of 2007, ‚Äúbiotechnology saw $1.5 billion in 102 deals, surpassing the software investments that traditionally receive the largest amount of capital.‚ÄĚ That created an environment in which companies in the United States, Europe, and ‚Äúemerging‚ÄĚ regions could provide some incentives for partnerships, mergers, or other deals (4). Biomanufacturers showed a renewed interest in outsourcing and other off-shore investments, and contract providers faced growing competition (5). To stay competitive, some contract manufacturers established themselves as one-stop providers (e.g., Vetter and Cook Pharmica)
By 2009, one of the busiest growth sectors was vaccines. Some of the largest pharmaceutical companies (e.g., Pfizer and Novartis AG) began to add vaccine development to their portfolios, which was nearly unheard of in the early 2000s. It meant adding capacity, both locally and overseas, boosting traditional outsourcing collaborations as well as partnerships built on innovation (6), although controlling costs remained a priority (7).
Today, vaccine manufacturing remains a healthy part of the industry. New segments in the industry are positioned for rapid growth as well, including biosimilars and cell therapies. Experts project a growing need in outsourcing services in such areas (e.g., Lonza, Florida Biologix, and MasTherCell provide services for cell therapies).
With increases in capital investments and outsourcing (and in-sourcing), network management, especially supply chain management, becomes even more important. As one author observed, ‚ÄúBuilding flexible plants that make reliable, consistent product to meet demand on-time is a vital cost-reducing goal that eliminates the need for the huge capital investments in new manufacturing facilities. Operational inefficiencies and the traditional ‚Äėlicense-and-leave‚Äô philosophy for building plants can cause capacity limitations at very real cost to manufacturers‚ÄĚ (8).
Strong supply chain management also ensures continued operation with uncompromised product quality should a change in raw material source occur. Companies should have investigational procedures in place for evaluating the possible effect of a raw-material change on a process or product (9).
Risk-based technology transfer strategies are fundamental to outsourcing (10, 11). Quality management systems can ensure a risk-based approach in several areas. For example, at the end of product and process development, a documented understanding of risks and their associated controls should be communicated during technology transfer to a commercial manufacturing operation or contractor. Also, risk profiles should be reviewed and updated during technology transfer. That ensures that ‚Äúno new risks have been introduced and that existing risk control measures are appropriate and effective‚ÄĚ (12). Thinking Globally
During the past 10 years, it became very clear that no real discussion about an evolving bioprocessing industry would be complete without addressing the growing markets outside of the United States. Early coverage of those markets described the biotechnology industry in India, Eastern Europe, and Asia (13,14,15). In 2002, Japan’s pharmaceutical market was worth US$53 billion, and China’s was worth ‚ąľ$23 billion (15).
About five years later, around 2007, China had captured the majority of the outsourcing market in Asia (16). And US manufacturers took interest, even while concerns remained over intellectual property protection, infrastructure, and regulatory oversight (17,18,19). A 2011 survey found that 17% of the industry considers China as the top future offshore production destination (18). Results also showed that sponsor companies are demanding that clients‚Äô product-specific manufacturing operations be kept proprietary. ‚ÄúThis factor is increasing in importance as a result of a general focus on outsourcing operations. Sponsors are demanding greater levels professionalism, performance, and effectiveness in both managerial and technical areas from their outsourcing vendors,‚ÄĚ (20). Manufacturing Locally
As manufacturers considered their options in markets overseas, they faced questions related to real costs of moving their operations or establishing a partnership with a local contract organization. Factors to take into consideration included logistics, cost of goods, infrastructure development, and export compliance.
BPI dedicated its June 2010 supplement (www.bioprocessintl.com/journal/supplements/2010/June) to those topics. And we held a panel discussion with industry experts at a 2011 conference (21). One interesting viewpoint was presented by Novavax CEO Rahul Singhvi, who spoke of efforts to locally produce vaccines for regional diseases using platform technologies and a modular facility. The result could be the future of outsourcing operations: ‚ÄúCan we possibly extend this approach by turning it into a franchise model? Could we have a turn-key technology transfer package?. . . . How might we turn this into a place where all that technology, all the science, all the ‚Äėart‚Äô can be turned into documentation so everybody can make vaccines ‚ÄĒ and make vaccines of the same quality? Then to take it to the next level, can we have in these ‚Äėfranchises‚Äô custom menus of products that address local needs? That’s the vision‚ÄĚ (21).
Maribel Rios is managing editor of BioProcess International; firstname.lastname@example.org.
1.) Langer, E. 2004. Manufacturing Capacity Put on Simmer. BioProcess Int. 2:22-28.
2.) Langer, ES. 2008. Biomanufacturing Capacity Use Showed Solid Performance in 2007. BioProcess Int. 6:28-32.
3.) Langer, E. 2007. Biopharmaceutical Production Outsourcing Matures. BioProcess Int. 5:32-37.
4.) Datin, JA. 2007. Good News for Entrepreneurs: Navigating Today’s Biotech Venture Capital Market. BioProcess Int. 5:14-20.
5.) Maynard, J. 2007. Supplier Innovation Is an Imperative: Five Steps to Achieving a Competitive Advantage. BioProcess Int. 5:22-30.
6.) Claude, Allary, Parker Michael, and Rhodes Sarah. 2009. Using Innovation to Drive Competitive Advantage. BioProcess Int. 7:10-17.
7.) Sinclair, A, and M. Monge. 2010. Measuring Manufacturing Cost and Its Impact on Organizations. BioProcess Int. 8:10-14.
8.) Johnston, R. 2008. Reconsidering the Supply Chain. BioProcess Int. 6:72.
9.) Toro, A. 2010. Changes in Raw Material Sources from Suppliers. BioProcess Int. 8:50-55.
10.) Rios, M. 2012. Risk-Based Strategies for Technology Transfer. BioProcess Int. 10:32-42.
11.) Lucy, PK, and RG. Beri. 2003. Key Considerations in Process Transfer. BioProcess Int. 1:36-44.
12.) DeSain, C. 2007. Risk-Based Quality Management Systems: What Are We Waiting For? BioProcess Int. 5:12-18.
13.) Feller, G. 2003. Indian Biotech on the Rise. BioProcess Int. 1:12-18.
14.) Baid, A. 2004. CRO Industry Rides High on Emerging Opportunities in Eastern Europe. BioProcess Int. 2:14-18.
15.) Gross, A. 2004. Biologics Regulation in Asia. BioProcess Int. 2:22-25.
16.) Zhou, Y. 2007. Opportunities in Biopharmaceutical Outsourcing to China. BioProcess Int. 5:16-23.
17.) Lee, P. 2008. Opening the Door to the Chinese Pharmaceutical Market. BioProcess Int. 6:24-30.
18.) Li, SX, and SM. Wheelwright. 2008. Partnering with a CMO in China. BioProcess Int. 6:S20-S23.
19.) Lee, ZJ, and XL. Ji. 2009. Creating an Effective Strategy for Offshoring to China 7:14-19.
20.) Langer, ES. 2011. China Ranked Top Potential Biopharma Outsourcing Destination. BioProcess Int. 10:S36-S40.
21.) Montgomery, SA. 2010. Geographic Strategies in Biomanufacturing. BioProcess Int. 8:42-49.